The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data
- 8 October 2009
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 114 (15), 3292-3298
- https://doi.org/10.1182/blood-2009-03-212969
Abstract
Currently, limited molecular markers exist that can determine where in the spectrum of chronic myeloid leukemia (CML) progression an individual patient falls at diagnosis. Gene expression profiles can predict disease and prognosis, but most widely used microarray analytical methods yield lengthy gene candidate lists that are difficult to apply clinically. Consequently, we applied a probabilistic method called Bayesian model averaging (BMA) to a large CML microarray dataset. BMA, a supervised method, considers multiple genes simultaneously and identifies small gene sets. BMA identified 6 genes (NOB1, DDX47, IGSF2, LTB4R, SCARB1, and SLC25A3) that discriminated chronic phase (CP) from blast crisis (BC) CML. In CML, phase labels divide disease progression into discrete states. BMA, however, produces posterior probabilities between 0 and 1 and predicts patients in “intermediate” stages. In validation studies of 88 patients, the 6-gene signature discriminated early CP from late CP, accelerated phase, and BC. This distinction between early and late CP is not possible with current classifications, which are based on known duration of disease. BMA is a powerful tool for developing diagnostic tests from microarray data. Because therapeutic outcomes are so closely tied to disease phase, these probabilities can be used to determine a risk-based treatment strategy at diagnosis.Keywords
This publication has 38 references indexed in Scilit:
- Positional gene enrichment analysis of gene sets for high-resolution identification of overrepresented chromosomal regionsNucleic Acids Research, 2008
- Diagnostic Markers for Early Detection of Ovarian CancerClinical Cancer Research, 2008
- MeV+R: using MeV as a graphical user interface for Bioconductor applications in microarray analysisGenome Biology, 2008
- Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemiaBMC Genomics, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Better therapeutics through microarraysNature Genetics, 2002
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences of the United States of America, 2001
- Model Selection and Accounting for Model Uncertainty in Graphical Models Using Occam's WindowJournal of the American Statistical Association, 1994
- Regressions by Leaps and BoundsTechnometrics, 1974
- VERIFICATION OF FORECASTS EXPRESSED IN TERMS OF PROBABILITYMonthly Weather Review, 1950